You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,514,415


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,514,415
Title:Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
Inventor(s): Klinman; Dennis (Potomac, MD), Zeuner; Rainald (Kiel, DE), Verthelyi; Daniela (Potomac, MD), Gursel; Ihsan (Rockville, MD), Gursel; Mayda (Rockville, MD)
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC) N/A (N/A)
Application Number:10/523,273
Patent Claims:1. A method of suppressing an immune response in an inflammatory arthritis in a subject comprising administering to a subject having an inflammatory arthritis a therapeutically effective amount of a substantially pure or isolated oligodeoxynucleotide of up to 100 nucleotides in length comprising the nucleotide sequence set forth as SEQ ID NO: 2 and an additional anti-inflammatory agent, immunosuppressive agent or anti-arthritis agent thereby suppressing the immune response in the inflammatory arthritis in the subject.

2. The method of claim 1, wherein the oligodeoxynucleotide is administered topically, parenterally, orally, intravenously, intra-muscularly, sub-cutaneously, or intra-articularly.

3. The method of claim 1, wherein the oligodeoxynucleotide consists of the nucleotide sequence set forth as SEQ ID NO: 2.

4. The method of claim 1, wherein the oligodeoxynucleotide further comprises a CpG motif, and comprises at least one TTAGGG motif 5' to the CpG motif.

5. The oligodeoxynucleotide method of claim 1, wherein the oligodeoxynucleotide further comprises a CpG motif, comprises a TTAGGG motif 3' to the CpG motif, and wherein the TTAGGG motif is separated from the CpG motif by at least ten nucleotides.

6. The method of claim 1, wherein the anti-inflammatory agent, immunosuppressive agent or anti-arthritis agent is a biological response modifier, a disease-modifying antirheumatic drug, a steroid, a nonsteroidal anti-inflammatory drug, or a Cyclo-Oxygenase-2 inhibitor.

7. The method of claim 1, wherein the anti-inflammatory agent, immunosuppressive or anti-arthritis agent is anakinra, etanercept, infliximab, leflunomide, prednisone, cortisone, celecoxib, choline magnesium trisalicylate, diclofenac, diclofenac potassium, diclofenac XR, diflunisal, etodolac, etodolac ER, fenoprofen, flurbiprofen oral, ibuprofen, indomethacin, indomethacin SR, indomethacin suppositories, ketoprofen, ketoprofen ER, meclofenamate, meloxicam, nabumetone, naproxen, naproxen CR, naproxen ER, oxaprozin, piroxicam, rofecoxib, salsalate, sulindac, or tolmetin sodium, hyaluronan, or hylan G-F20.

8. A method of suppressing an immune response in an inflammatory arthritis in a subject comprising contacting immune cells with a therapeutically effective amount of a substantially pure or isolated oligodeoxynucleotide comprising the nucleotide sequence set forth as SEQ ID NO: 2, and transferring the immune cells to a subject having inflammatory arthritis, thereby suppressing the immune response in the inflammatory arthritis in the subject.

9. The method of claim 1, wherein the oligodeoxynucleotide is modified to prevent degradation.

10. The method of claim 9, wherein the oligodeoxynucleotide comprises a phosphate backbone modification.

11. The method of claim 8, wherein the oligodeoxynucleotide consists of the nucleotide sequence set forth as SEQ ID NO: 2.

12. The method of claim 8, wherein the oligodeoxynucleotide is modified to prevent degradation.

13. The method of claim 12, wherein the oligodeoxynucleotide comprises a phosphate backbone modification.

14. The method of claim 8, wherein the oligodeoxynucleotide consists of SEQ ID NO: 2.

Details for Patent 7,514,415

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 08/24/1998 ⤷  Try a Trial 2022-08-01
Immunex Corporation ENBREL etanercept For Injection 103795 11/02/1998 ⤷  Try a Trial 2022-08-01
Immunex Corporation ENBREL etanercept For Injection 103795 05/27/1999 ⤷  Try a Trial 2022-08-01
Immunex Corporation ENBREL etanercept Injection 103795 09/27/2004 ⤷  Try a Trial 2022-08-01
Immunex Corporation ENBREL etanercept Injection 103795 02/01/2007 ⤷  Try a Trial 2022-08-01
Immunex Corporation ENBREL MINI etanercept Injection 103795 09/14/2017 ⤷  Try a Trial 2022-08-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.